Lechleiter was a high-level player within Lilly in recent years while the companyâ??s stock performed at mediocre levels, CALPERS says.
Is Lechleiter the problem?
Or is he being blamed for any problems that his predecessor, Sidney Taurel, might have created, or even for the overall sluggishness in the pharmaceutical industry?
What do you think?